trial · primary record
Durvalumab
Small Cell Lung Carcinoma
| Phase | Phase 3 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 71 |
| Primary completion | 2029-06-30 |
| Primary endpoint | To describe the safety profile of durvalumab for patients with LS-SCLC who have not progressed following CRT. |
| Registry ID | NCT06992609 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T03:27:45.467Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06992609
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.